D-0279-2022 Class II Terminated
FDA drug recall D-0279-2022 was initiated by Teligent Pharma, Inc. on Oct 12, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent. The recall status is terminated (terminated Jun 18, 2024). Affected quantity: 7,008 glass bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 22, 2021
- Initiation Date
- Oct 12, 2021
- Termination Date
- Jun 18, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7,008 glass bottles
Product description
Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL glass bottles, Rx Only, Manufactured by: Teligent Pharma Inc., Buena, NJ 06310, Distributed by: McKesson Corporation dba Sky Packaging, 497 Southridge Blvd, Suite 101, Memphis, TN 36141, NDC 63739-997-64.
Reason for recall
CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent.
Distribution pattern
Nationwide within the United States
Code information
Lot #: 16306, Exp. Date 01/2024.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0279-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026